Fig. 7: Evaluation of GX1 effect on the TGM2 subcellular distribution, TGM2 G-protein activity and the expression of intracellular-TGM2 downstream molecular targets.

a Western blotting analysis of TGM2 in total protein samples and membrane protein samples of co-HUVECs treated with or without GX1 (0.1 mg/ml, 24 h) when TGM2 expression was downregulated. **P < 0.01; n = 3. b The GX1 (0.1 mg/ml, 24 h) effect on the subcellular distribution of TGM2 in co-HUVECs by immunofluorescence. c The GX1 (0.1 mg/ml, 24 h) effect on the subcellular distribution of TGM2 in co-HUVECs by immunoelectron microscopy (a-1 represents a schematic of a; b-1 represents a schematic of b). The TGM2 distribution in the control was indicated by blue arrows. The TGM2 distribution in co-HUVECs treated with GX1 was indicated by red arrows. d Alteration of the GTP-binding activity of TGM2 in co-HUVECs treated with GX1 (0.1 mg/ml, 24 h). e The GX1 (0.1 mg/ml, 24 h) effect on the mRNA expression of NF-κB and HIF1α in co-HUVECs. ***P < 0.001; n = 3. f The GX1 (0.1 mg/ml, 24 h) effect on the expression of NF-κB and HIF1α at the protein level in co-HUVECs. *P < 0.05; n = 3. g A schematic illustration of the mechanism through which GX1 inhibits angiogenesis in gastric cancer